3-Amino-2-pyridinecarboxylic acid:Exports & Compliance White Paper 2026

I. Executive Summary

3-Amino-2-pyridinecarboxylic acid (CAS 1462-86-8), also written 3-aminopicolinic acid, is a heteroaryl amino acid of formula C6H6N2O2 and molecular weight 138.13 that combines a pyridine ring nitrogen, a ring amino group and a carboxylic acid in one compact scaffold. The ring nitrogen and carboxylate form a chelation site, while the amine is the derivatisation point for amides, ureas and sulfonamides. It is supplied as the free acid and increasingly as hydrochloride or alkali-metal salts.

Commercially the molecule behaves as a custom-synthesis item rather than a commodity. Volumes run from kilograms to a few tonnes and campaigns are tied to a customer programme, with price set by route choice, analytical depth and quality-system grade. Buyers therefore differentiate less on assay than on three things: regioisomeric purity of the amino and carboxyl placement, the residual metal profile left by the reduction or coupling step, and the completeness of the genotoxic-impurity assessment for the aromatic amine.

Three technical risks dominate: decarboxylation under heat, which constrains drying and storage; chelation of trace metals, which drives colour, assay drift and ICH Q3D discussions; and the arylamine mutagenicity question, which needs data rather than assertion. Add REACH, CLP and TSCA as gating items, and the differentiator becomes documentation discipline rather than nominal capacity.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The scaffold is a 2,3-disubstituted pyridine: a carboxylic acid adjacent to the ring nitrogen and an amino group next to the acid. Because the ring nitrogen is basic and the acid is acidic, the molecule exists largely as a zwitterion, which explains its poor solubility in neutral water, high melting point and readiness to form salts.

• Zwitterionic behaviour and salt formation: Internal proton transfer gives a high-melting, highly polar solid with poor solubility in neutral water and in most solvents other than DMSO, DMF and NMP. Solubility rises sharply at low pH, where ring nitrogen and amine are protonated, and at high pH, where the carboxylate forms. The free acid, the hydrochloride and the sodium or potassium salts are therefore different products, and buyers must specify which form they are qualifying.
• Decarboxylation risk and thermal stability: Picolinic acids decarboxylate more readily than benzoic acids because the ring nitrogen stabilises the transition state, and the amino substituent further reduces the thermal margin. DSC and TGA screening should precede any fixed drying or milling step, and drying should run under vacuum at controlled temperature. Storage specifications should state a maximum temperature and a defined retest period rather than an open-ended shelf life.

2.2 Synthesis and Manufacturing Technologies

Published and industrial practice converges on two route classes, and the choice between them determines which impurities the analytical method has to resolve. Both are legitimate industrial chemistry; the question for the buyer is which impurity legacy they prefer to inherit.

• Nitration-reduction route: Picolinic acid or a pyridine-2-carboxylate ester is nitrated at the 3-position, and the nitro group is reduced by catalytic hydrogenation, a metal-acid system or transfer hydrogenation. The route is short and cheap but leaves a nitroaromatic legacy: residual nitro and nitroso species are ICH M7 concerns, and reduction metals enter the ICH Q3D discussion. Control depends on a validated HPLC method resolving the nitro precursor, the amine and the positional isomers.
• Hofmann rearrangement and carboxamide-based routes: Starting from quinolinic acid or a monoamide, a 3-carbamoylpicolinic acid is subjected to Hofmann rearrangement with hypohalite, or to a Curtius or Schmidt variant, to contract the carbon by one and install the amine; other variants use directed metalation and carboxylation of 3-aminopyridine derivatives. These routes avoid nitroaromatic intermediates entirely, a material advantage for pharmaceutical supply, but trade that for more steps, hypohalite handling and cryogenic organolithium operations that constrain scale.

2.3 Core Application Matrix

• Agrochemical scaffold: Aminopicolinic acids sit at the structural core of the pyridine-carboxylate herbicide family, and the 3-amino-2-carboxy arrangement is used in discovery programmes for herbicides and insecticides. Demand is project-driven and lumpy, tied to a registrant's development timeline and to national pesticide registration.
• Pharmaceutical building block: The scaffold appears in medicinal chemistry as a rigid, polar, metal-chelating fragment and as a precursor to fused bicyclic heteroaryl systems; the amino group is typically acylated, sulfonylated or converted into a urea, and the acid is coupled to amines. Material is supplied research-grade or GMP depending on programme stage, with documentation depth following the customer's regulatory position.
• Ligands, coordination chemistry and materials: The donor set of pyridine nitrogen, carboxylate and amino group makes the molecule useful as a chelating ligand for transition-metal complexes, in metal-organic framework research, and as a corrosion-inhibiting and surface-treatment additive. Volumes are small but absorb development quantities and justify keeping a catalog specification alive.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand for 3-aminopicolinic acid is project demand. Agrochemical and pharmaceutical discovery generate kilogram enquiries that either die at candidate selection or convert into multi-hundred-kilogram GMP campaigns, with little in between. Two shifts are visible in 2026: customers increasingly specify the salt form and a regioisomerically defined specification up front rather than accepting catalog material, and they move straight to a CDMO arrangement to control the impurity narrative from the first gram. Growth is therefore uneven and concentrated in a few named programmes.

3.2 Capacity Distribution and Export Flows

China supplies most merchant material, with heterocyclic custom-synthesis capacity in Jiangsu, Shandong, Zhejiang and Hubei integrated back to pyridine and picoline feedstocks. India's position rests on CDMO and contract-research capacity in Hyderabad, Bengaluru and Gujarat, where the molecule is made inside multi-step programmes rather than held as catalog stock, supported by FDA- and EMA-inspected sites. The European Union, and to a lesser extent Japan and Korea, holds smaller, higher-cost capacity focused on early-phase GMP and route development. Flows therefore run from China and India toward European and North American innovators.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is quotation-based rather than index-based. Hydrogenation routes price off catalyst, hydrogen pressure capability and metal removal; Hofmann routes price off step count, hypohalite handling and effluent treatment; and in both cases the analytical package can add as much per kilogram as the chemistry itself, because HPLC isomer resolution, ICP-MS metal screening and a genotoxic assessment are scarce skills. Buyers should normalise quotations on specification, salt form and analytical scope, since two prices for the same CAS number frequently describe different products.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

As a low-volume, high-documentation intermediate, this molecule is governed less by tonnage than by the end use of the customer's product. Exporters should expect the customer's regulatory questions to be pushed down the chain.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration and CLP classification: The substance must be registered, or covered by a valid registration, for the tonnage imported into the EU, with non-EU manufacturers working through an only representative. Classification under CLP drives pictograms, labelling and the transport description, and buyers should confirm that the notification covers the specific salt form shipped, since hydrochloride and free acid can differ.
• Sector rules for agrochemical and pharmaceutical end use: Where the material feeds a plant-protection product, active-substance approval under Regulation (EC) 1107/2009 and national authorisation sit with the registrant, but impurity and residue data must be traceable back to the intermediate. Where it feeds a medicinal product, the intermediate is captured by the customer's ICH Q11 route description and by GMP expectations under ICH Q7, and the supplier may be asked to support a drug master file.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory status and EPA considerations: Confirm active TSCA Inventory listing for CAS 1462-86-8 before first shipment, verify Chemical Data Reporting obligations and any applicable significant new use rule, and hold written inventory-status certification. Where the material supports a pesticide, EPA registration under FIFRA applies to the finished product, and the intermediate supplier should expect requests for composition and impurity disclosure under confidentiality agreements.
• FDA-facing quality expectations for pharmaceutical programmes: Material entering an investigational or marketed supply chain is assessed against ICH Q7 for the GMP chain, ICH Q11 for route and lifecycle description, ICH Q3C for residual solvents and ICH Q3D for elemental impurities, with an ICH M7 assessment for the aromatic amine and any nitroaromatic carryover. Suppliers should expect audits, written quality agreements and change-control notification rather than simple assay quotations.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Even at kilogram scale, ESG questions reach the supplier, because innovator customers report solvent footprints and Scope 3 emissions across their development portfolios.

5.1 Carbon Footprint and Circular Economy

The footprint of a multi-step heterocyclic synthesis is dominated by solvent use and by the number of isolations rather than by stoichiometric reagents. Route mass intensity, solvent recovery by distillation, and the replacement of DMF, NMP and chlorinated solvents with recoverable alcohols, esters or 2-methyltetrahydrofuran are the credible levers, and they are increasingly written into CDMO service agreements. Suppliers should show ISO 14001 certification, report Scope 1 and 2 inventories and quote process mass intensity per campaign.

5.2 Sustainable Sourcing and Traceability

Traceability expectations mirror pharmaceutical practice: full batch genealogy from purchased pyridine or picoline feedstock to the released lot, certificates of analysis for each starting material, and documented control of any substance of concern. Customers increasingly ask for conflict-minerals and responsible-sourcing declarations, for modern-slavery statements where they report under UK or Australian legislation, and for confirmation of equipment-cleaning status. Because campaigns often run on shared equipment, buyers should confirm whether a train is dedicated or multipurpose.

VI. Supply Chain Resilience and Export Logistics

This is a stable, high-melting, non-volatile solid, so the logistics risks are moisture, electrostatic handling and cross-contamination rather than temperature or pressure.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture-tight, fibre-free packaging: Pack in double polyethylene liners inside fibre drums or HDPE containers, add desiccant where specified and seal under nitrogen if the salt form is hygroscopic, avoiding paper or cardboard contact. Specify loss on drying and appearance at release and set a retest period with a stated temperature ceiling, since decarboxylation makes an open ambient shelf life inappropriate.
• Contamination control and documentation for GMP campaigns: For GMP campaigns the packaging and cleaning story is auditable: cleaning validation with swab and rinse limits derived from the permitted daily exposure, line-clearance records, retained samples, and a certificate of analysis carrying actual batch values for assay, isomers, metals and residual solvents. Buyers should require the swab-limit calculation itself, not merely a statement that equipment was cleaned.

6.2 Dangerous Goods Identification and Transit Protocols

Most shipments are not dangerous goods, but the classification must come from the current SDS for the exact salt form, since some aminopyridine and aromatic amine entries attract acute-toxicity classification with its own packing group. Where a hazard classification applies, IMDG, ADR/RID and IATA govern packaging and marking; otherwise the controls are moisture barriers, desiccant, sealed liners and earthing. No cold chain is required for the free acid, but temperature-logged transport is sensible for hygroscopic salts and humid routes, and air freight is common for development quantities.

VII. Enterprise Global Expansion Strategy Guide

Three actions determine whether a buyer obtains a usable, auditable supply position for this scaffold.

1. Qualify the route, not just the supplier: Ask which route class is used and what impurity legacy follows, then write the answer into the specification. A nitro-reduction supplier and a Hofmann-route supplier need different analytical methods and different purge arguments, and knowing which one you have avoids a late change-control event.
2. Fix the analytical package at the quotation stage: Require a resolving HPLC method for regioisomers, LC-MS identity confirmation, ICP-MS for ICH Q3D elements, GC for ICH Q3C solvents, and an ICH M7 assessment covering both the arylamine product and the nitroaromatic intermediate. Agree the method, limits and change-control trigger before the first batch.
3. Contract for CDMO behaviour: Use a quality agreement covering starting-material selection, cleaning validation, change control, audit rights, retained samples and the format of the development report. Confirm REACH, TSCA and CLP status in writing for the specific form shipped, require ISO 9001 and ISO 14001 certification, and tie campaign pricing to a defined specification.

VIII. Conclusion

3-Aminopicolinic acid is a small heteroaryl fragment whose commercial value is created almost entirely by documentation. The chemistry is accessible from more than one route, so what distinguishes suppliers is whether they can resolve the regioisomers, screen the metals this scaffold chelates, answer the arylamine question with data, and dry the product without decarboxylating it. Buyers who define those requirements at the enquiry stage receive comparable quotations; buyers who ask only for assay receive surprises at the first regulatory review.

The outlook is stable and project-driven. Agrochemical and pharmaceutical discovery keep generating enquiries, the shift toward CDMO-based development is strengthening, and the Chinese, Indian and European ecosystems serve different needs: scalable heterocyclic capacity in China, programme-integrated custom synthesis in India, and early-phase GMP and route development in Europe. Sourcing that matches the tier to the programme stage is the position that survives candidate selection.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 3-Amino-2-pyridinecarboxylic acid Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 3-Amino-2-pyridinecarboxylic acid supply chain:

• China - integrated heterocyclic capacity: The largest merchant base, concentrated in Jiangsu, Shandong, Zhejiang and Hubei, with access to pyridine and picoline feedstocks and to catalytic hydrogenation at pressure. Strengths are route breadth, quotation speed and cost at the kilogram-to-hundred-kilogram scale; watch points are the depth of the genotoxic-impurity argument and metal-residue data.
• India - programme-integrated CDMO ecosystem: Centred on Hyderabad, Bengaluru and Gujarat, where the molecule is typically produced inside multi-step programmes rather than held as stock. Strengths are English-language regulatory documentation, ICH Q7 and Q11 experience and FDA- and EMA-inspected facilities; watch points are lead time for route development and higher cost per kilogram.
• European Union - early-phase GMP and route development: Smaller and more expensive, but strongest where the customer is still choosing the route. Strengths are REACH-registered supply, mature CLP and SDS practice, ISO 9001 and ISO 14001 certification, and willingness to run the screening and thermal-hazard work that de-risks scale-up; constraints are cost and limited appetite for large-volume campaigns.